Organ transplantation is one of the miracles in medicine in the 20th century. However, in the current practice, all the donor organs suffer from ischemia/reperfusion injury (IRI), which compromises transplant outcomes, limits organ availability, and increases cancer recurrence. In 2017, ischemia-free organ transplantation (IFOT) was first proposed by our group with the aim of complete avoidance of IRI in organ transplantation. The feasibility of IFOT has been validated in liver, kidney, and heart transplantation. The results of the first non-randomized controlled study demonstrate that ischemia-free liver transplantation (IFLT) can improve transplant outcomes and increase organ availability. Furthermore, laboratory results demonstrate the absence of the characteristic pathological changes, gene transcription, and metabolic reprogramming, as well as sterile inflammation activation in IFLT grafts, suggesting the virtual avoidance of graft IRI in IFLT. In 2023, we published the results of the first randomized trial of IFLT and showed that IFLT can significantly reduce the incidence of IRI-related complications.